申请人:Yoshitomi Pharmaceutical Industries, Ltd.
公开号:US05124331A1
公开(公告)日:1992-06-23
3,4-Dihydrothieno[2,3-d]pyrimidine compounds having immunoregulating and carcinostatic actions of the general formula ##STR1## wherein A represents a C.sub.1-4 alkylene; R.sup.1 represents hydrogen, an alkyl, an aryl which may be substituted or --N(R.sup.7)(R.sup.8); R.sup.2, R.sup.3 and R.sup.4 represent hydrogen, a halogen, hydroxy, an alkyl which may be substituted by a halogen, an alkoxy, nitro, cyano or --N(R.sup.9)(R.sup.10); R.sup.5 represents hydrogen, a halogen, nitro, amino, cyano, an alkyl or an alkoxycarbonyl; R.sup.6 represents hydrogen, a halogen, nitro, amino, cyano, an alkyl, an alkoxycarbonyl, a halogenosulfonyl or --SO.sub.2 N(R.sup.12)(R.sup.13); or R.sup.5 and R.sup.6 may, taken together, form a C.sub.3-6 alkylene chain, and their pharmaceutical use.
具有免疫调节和抗癌作用的3,4-二氢噻吩[2,3-d]嘧啶化合物的一般结构式为##STR1##其中A代表C.sub.1-4烷基; R.sup.1代表氢、烷基、可能被取代的芳基或--N(R.sup.7)(R.sup.8); R.sup.2、R.sup.3和R.sup.4代表氢、卤素、羟基、可能被卤素取代的烷基、烷氧基、硝基、氰基或--N(R.sup.9)(R.sup.10); R.sup.5代表氢、卤素、硝基、氨基、氰基、烷基或烷氧羰基; R.sup.6代表氢、卤素、硝基、氨基、氰基、烷基、烷氧羰基、卤烷基磺酰基或--SO.sub.2 N(R.sup.12)(R.sup.13); 或者R.sup.5和R.sup.6可能联合形成C.sub.3-6烷基链,以及它们的药用。